X0306 4 2017-02-28 0001681689 Bioverativ Inc. BIVV 0001498428 Cox John BIOVERATIV INC. 225 2ND AVE. WALTHAM MA 02451 1 1 Chief Executive Officer Common Stock 2017-02-28 4 A 0 211679 0 A 226979 D Common Stock 2017-02-28 4 F 0 3404 43.42 D 223575 D Common Stock 2017-02-28 4 F 0 3383 49.56 D 220192 D Common Stock 2017-02-28 4 F 0 8355 47.76 D 211837 D Common Stock 2017-02-28 4 F 0 6986 43.42 D 204851 D Common Stock 2017-02-28 4 F 0 2641 49.56 D 202210 D Common Stock 2017-02-28 4 F 0 6436 47.76 D 195774 D Common Stock 2017-02-28 4 F 0 6726 43.42 D 189048 D Non-Qualified Stock Option 7.82 2017-02-28 4 A 0 48230 0 A 2019-02-23 Common Stock 48230 48230 D Non-Qualified Stock Option 9.53 2017-02-28 4 A 0 18381 0 A 2018-02-11 Common Stock 18381 18381 D Includes restricted stock units granted by Bioverativ Inc. ("Bioverativ") to the reporting person as a result of the conversion of existing Biogen Inc. ("Biogen") cash-settled performance units, market stock units and restricted stock units held by the reporting person prior to the spin-off of Bioverativ from Biogen on February 1, 2017 ("Spin-off"), as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off. Restricted stock units that are unvested continue to vest on the dates of the original Biogen awards. Includes 15,300 shares acquired in a pro rata distribution by Biogen in connection with the Spin-Off. Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Represents stock options to purchase Bioverativ common stock granted to the reporting person as a result of the conversion of existing Biogen stock options held by the reporting person prior to the Spin-Off, as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off. This option is presently exercisable in full. /s/ Matthew S. Gilman, Attorney in Fact for John Cox 2017-03-02